Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous vs placebo
Oral mucositis (severe) · Adults with cancer receiving treatment
Keratinocyte growth factor (KGF; palifermin or repifermin),… may leads to lower oral mucositis (severe) compared with placebo (low certainty).
3 findings from 1 review
- Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomesChemotherapy alone for mixed cancersRR 0.30 [0.14, 0.65]3 studies · 263 participantsLow
- Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomesBMT/SCT after conditioning for haematological cancersRR 0.85 [0.65, 1.11]6 studies · 852 participantsLow
- Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomesRT to head and neck with cisplatin/fluorouracilRR 0.79 [0.69, 0.90]3 studies · 471 participantsHigh